Ruchika Pokhriyal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ruchika Pokhriyal has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Ashish Kumar Gupta
Department of Biophysics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
1 shared publication- Ashok Kumar Mohanty
Central Institute for Research on Cattle
1 shared publication - Divya Gupta
Northwestern University, Feinberg School of Medicine, Chicago, IL
1 shared publication - Gururao Hariprasad
Department of Biophysics, All India Institute of Medical Sciences, Ansari nagar, New Delhi, 110029, India
1 shared publication - Jasmine Naru
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center
1 shared publication - Lalit Kumar
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hajipur, Patna, Bihar, India
1 shared publication
Latest Publications
- Open Access
- 1 January 2016
- Published by SAGE Publications in Biomarkers in Cancer
- Vol. 8, BIC.S35775-56
Comparative Proteomic Analysis of Advanced Ovarian Cancer Tissue to Identify Potential Biomarkers of Responders and Nonresponders to First-Line Chemotherapy of Carboplatin and Paclitaxel
Conventional treatment for advanced ovarian cancer is an initial debulking surgery followed by chemotherapy combination of carboplatin and paclitaxel. Despite initial high response, three-fourths of these women experience disease recurrence with a dismal prognosis. Patients with advanced-stage ovarian cancer who underwent cytoreductive surgery were enrolled and tissue samples were collected. Post surgery, these patients were started on chemotherapy and followed up till the end of the cycle. Fluorescence-based differential in-gel expression coupled with mass spectrometric analysis was used for discovery phase of experiments, and real-time polymerase chain reaction, Western blotting, and pathway analysis were performed for expression and functional validation of differentially expressed proteins. While aldehyde reductase, hnRNP, cyclophilin A, heat shock protein-27, and actin are upregulated in responders, prohibitin, enoyl-coA hydratase, peroxiredoxin, and fibrin-β are upregulated in the nonresponders. The expressions of some of these proteins correlated with increased apoptotic activity in responders and decreased apoptotic activity in nonresponders. Therefore, the proteins qualify as potential biomarkers to predict chemotherapy response.
- 1 January 2016
- Published by SAGE Publications in Biomarkers in Cancer
- Vol. 8, BIC.S35775-56
Open AccessComparative Proteomic Analysis of Advanced Ovarian Cancer Tissue to Identify Potential Biomarkers of Responders and Nonresponders to First-Line Chemotherapy of Carboplatin and Paclitaxel
Conventional treatment for advanced ovarian cancer is an initial debulking surgery followed by chemotherapy combination of carboplatin and paclitaxel. Despite initial high response, three-fourths of these women experience disease recurrence with a dismal prognosis. Patients with advanced-stage ovarian cancer who underwent cytoreductive surgery were enrolled and tissue samples were collected. Post surgery, these patients were started on chemotherapy and followed up till the end of the cycle. Fluorescence-based differential in-gel expression coupled with mass spectrometric analysis was used for discovery phase of experiments, and real-time polymerase chain reaction, Western blotting, and pathway analysis were performed for expression and functional validation of differentially expressed proteins. While aldehyde reductase, hnRNP, cyclophilin A, heat shock protein-27, and actin are upregulated in responders, prohibitin, enoyl-coA hydratase, peroxiredoxin, and fibrin-β are upregulated in the nonresponders. The expressions of some of these proteins correlated with increased apoptotic activity in responders and decreased apoptotic activity in nonresponders. Therefore, the proteins qualify as potential biomarkers to predict chemotherapy response.